PDC line Pharma 

Spin-off of French Blood Bank (EFS, Etablissement Français du Sang)

SAS founded in April 2014 in Grenoble, France

SA founded in June 2016 in Liège (Belgium)

Funding

The company has raised 7,6 M€ in equity on the top of 9,3 M€ of non-dilutive money and is looking to close a new financing round in 2019 to finance a phase 1b / 2 clinical proof of concept study in lung cancer.

In march 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countriesto LG Chem Life Sciences Company, for the development and commercialization of PDC*lungcancer vaccine for lung cancer. The total deal value is 108M€ (123M$) plus significant tieredroyalties on net sales in Asia.

PDC*line Pharma won numerous awards, including the first prize of the French start-up competition “Tremplin Entreprises” in the biotech category in 2015, and the first prize of the MATWIN oncology projects competition in the start-up category awarded by international leaders from the pharmaceutical industry and academic research.

Management team

Eric Halioua (MS, MBA),  President & Chief Executive Officer

Laurent Levy (MS, MBA), Cofounder & Chief Operating Officer

Joel Plumas (PhD), Cofounder & Chief Scientific Officer

Claude Dedry (Pharm. D), Vice-President Pharmaceutical Operations & Quality

Board of Directors

Eric Halioua (MS, MBA), President

Laurent Levy (MS, MBA)

Joel Plumas (PhD)

Alain HERRERA (Medical oncologist)

Jean-Paul PRIEELS (PhD)

Joanna TYREKIDIS (MBA)

François Fontaine

Pierre DETRIXHE, Observer

Products

• New class of antigen presenting cell – cancer vaccine
• Based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells (PDC*line)
• Target: clinical Proof of Concept by 2021